Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01995643 · ClinicalTrials.gov registry record · NA

Acute Effects of Grape Seed Extract on Insulin Sensitivity and Oxidative Stress and Inflammation Markers.

A NA study, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.

Completed
Registry status
NA
Development phase
13
Enrollment target

NCT01995643: Completed NA study, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.

NCT01995643 is a NA study that has completed, run by Clinical Nutrition Research Center, Illinois Institute of Technology. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01995643, a NA study, has completed, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.

COMPLETED
Registry status
NA
Development phase
13 participants
Enrollment target

Study Summary

The proposed study aims to investigate that consumption of grape seed extract (GSE) would improve antioxidant status and impaired insulin action following consumption of a pro-oxidative high carbohydrate, high fat (HCHF) meal in healthy human subjects.

Primary Outcome

The timing influence of the Grape Seed Extract administration on insulin and glucose concentrations in relative to the standard meal intake (1 hour before the meal and 5 hours after the meal)

Interventions

  • DIETARY_SUPPLEMENT Placebo Capsule
  • DIETARY_SUPPLEMENT Active Capsule

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2013-10-01
Est. Completion 2014-08-30
Phase NA

What the finished NCT01995643 record still lists

NCT01995643 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo Capsule is the first listed.

NCT01995643 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01995643 about?

NCT01995643 is a clinical study titled "Acute Effects of Grape Seed Extract on Insulin Sensitivity and Oxidative Stress and Inflammation Markers.". The proposed study aims to investigate that consumption of grape seed extract (GSE) would improve antioxidant status and impaired insulin action following consumption of a pro-oxidative high carbohydrate, high fat (HCHF) meal in healthy human subjects.

What is the current status of trial NCT01995643?

This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2013-10-01. Estimated completion is 2014-08-30.

What interventions are being tested in trial NCT01995643?

The interventions under investigation include: Placebo Capsule (DIETARY_SUPPLEMENT), Active Capsule (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01995643?

This trial is sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology, which has 59 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01995643's enrollment target sits among peer trials

13 1911th of 2000 higher than 88 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03125655 · 13 participants

    Regulation of Inflammatory Genes in Psoriasis

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01995643, the US trial registry maintained by the National Library of Medicine. NCT01995643 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.